Goldman Sachs initiates coverage on Braveheart Bio with Buy, $48 target
- Goldman Sachs initiates coverage on Braveheart Bio (NASDAQ: BRVE)
- Analyst Salveen Richter assigns a Buy rating to the stock
- Price target is set at $48 per share

*this image is generated using AI for illustrative purposes only.
Goldman Sachs has initiated coverage on Braveheart Bio (NASDAQ: BRVE), assigning a Buy rating and setting a price target of $48. The coverage initiation was led by analyst Salveen Richter.
Analyst Recommendation
The investment bank’s research team views the stock favorably based on its initial assessment. The $48 price target reflects the firm's valuation model for the company at this stage.
Key Details
- Analyst: Salveen Richter
- Rating: Buy
- Price Target: $48
- Ticker: NASDAQ: BRVE
What specific clinical milestones or regulatory approvals underpin Goldman Sachs' $48 price target for Braveheart Bio?
How does the current valuation of BRVE compare to other mid-cap biotech firms recently initiated by major investment banks?
What are the primary downside risks that could lead Goldman Sachs to downgrade the Buy rating in the near future?


























